Patient-Derived Gastric Cancer Assembloids for Drug Response Modeling

Study Background and Research Question

Gastric cancer remains a leading cause of cancer mortality worldwide, with limited therapeutic options and poor five-year survival rates for advanced cases (Shapira-Netanelov et al., 2025). A central challenge in translational oncology is the mismatch between preclinical models and the complex cellular heterogeneity of patient tumors, especially the roles of diverse stromal populations in modulating drug resistance. Conventional three-dimensional organoid cultures, while valuable, often lack the full spectrum of tumor–stroma interactions and thus fall short in predicting clinical responses. This study addresses the gap by developing a novel assembloid model, asking: can integrating matched stromal subpopulations with tumor organoids yield a more accurate preclinical platform for dissecting drug responses and resistance mechanisms?

Key Innovation from the Reference Study

The primary innovation is the establishment of patient-derived gastric cancer assembloids that combine tumor epithelial organoids with autologous stromal cell subtypes isolated from the same tumor specimen. Unlike conventional organoids, these assembloids recapitulate the full cellular heterogeneity and microenvironmental cues of primary gastric tumors. The inclusion of matched stromal subpopulations—such as mesenchymal stem cells, fibroblasts, and endothelial cells—enables the study of tumor–stroma crosstalk, gene expression shifts, and drug response variability at a level not previously accessible in vitro (Shapira-Netanelov et al., 2025).

Methods and Experimental Design Insights

The researchers employed a multi-step protocol:

• Tumor tissue dissociation: Fresh gastric tumor samples were enzymatically and mechanically dissociated to yield single-cell suspensions.
• Cell population expansion: Distinct growth media were used to selectively expand tumor epithelial cells (for organoids), mesenchymal stem cells, fibroblasts, and endothelial cells.
• Assembloid formation: Matched cellular populations were co-cultured in an optimized medium supporting the viability and function of each cell type.
• Characterization: Biomarker expression was validated by immunofluorescence, and transcriptomic profiles were generated via RNA sequencing. Drug sensitivity was assessed using cell viability assays following exposure to various chemotherapeutic and targeted agents.

This integrated workflow enabled systematic analysis of how stromal composition influences both the molecular phenotype and therapeutic response of the assembloids.

Protocol Parameters

• assay | cell viability (ATP-based) | typically 72 h | assessment of drug response in organoids/assembloids | paper
• assay | immunofluorescence marker expression | endpoint (post-culture) | confirmation of cell subtype identities | paper
• assay | RNA-seq transcriptomics | after assembly and drug exposure | profiling of gene expression and pathway activation | paper
• assay | co-culture medium optimization | custom composition per cell type | ensures physiological relevance of interactions | workflow_recommendation

Core Findings and Why They Matter

The assembloid model demonstrated several key advantages over standard organoid or monoculture systems:

• Enhanced heterogeneity: The cellular composition of assembloids closely matched that of primary tumors, as confirmed by both marker expression and transcriptomics (Shapira-Netanelov et al., 2025).
• Stromal influence on drug response: Drug screening across multiple patient-derived models revealed that some agents lost efficacy in the presence of stromal cells, emphasizing the importance of tumor–microenvironment interactions in modulating sensitivity and resistance.
• Inflammatory and extracellular matrix signatures: Assembloids showed increased expression of cytokines and matrix remodeling genes, recapitulating features linked to tumor progression and therapeutic evasion.
• Personalized screening potential: The system supports high-content analysis for individualized drug response prediction, potentially informing more effective combination therapies.

These findings reinforce the need to move beyond epithelial monocultures in preclinical testing, especially when evaluating agents that target DNA damage and apoptosis induction or rely on microenvironmental modulation.

Comparison with Existing Internal Articles

Previous coverage has focused on colorectal cancer models, particularly with respect to the application of Irinotecan (CPT-11) as a tool for DNA damage and apoptosis induction, and for tumor growth suppression in xenograft models (YTBroth workflow guide; SN-38.com review). These resources detail Irinotecan's mechanistic activity as a topoisomerase I inhibitor and its reproducible efficacy in colorectal cancer cell line inhibition and animal models. However, they acknowledge a key limitation: traditional 2D and 3D monocultures often fail to predict clinical responses due to suboptimal modeling of the tumor microenvironment. The assembloid methodology presented in the current gastric cancer study provides a direct solution to this limitation by integrating physiologically relevant stromal interactions, an approach advocated in recent workflow recommendations for advanced anticancer prodrug testing.

Limitations and Transferability

While the assembloid platform marks a significant step forward in recapitulating in vivo-like tumor environments, several limitations should be noted:

• Establishment and maintenance of patient-derived assembloids is labor-intensive and technically demanding.
• There is inherent variability in stromal composition and functional phenotypes across patient samples, posing challenges for standardization.
• The model is optimized for gastric cancer and may require significant adaptation for other tumor types, especially those with unique microenvironmental features.
• Drug response in assembloids, while more predictive than monocultures, may still not fully capture systemic pharmacokinetics or immune-mediated effects.

Nevertheless, the study provides a reproducible framework that can be adapted for other solid tumor research, offering insights into resistance mechanisms and personalized therapy design (Shapira-Netanelov et al., 2025).

Research Support Resources

For researchers aiming to translate these insights into experimental workflows—whether in gastric or colorectal cancer research—access to rigorously characterized compounds and optimized protocols is essential. Irinotecan (CPT-11, SKU A5133) is widely used to model DNA damage and apoptosis induction, as well as to evaluate tumor growth suppression in xenograft models. APExBIO provides Irinotecan with detailed product specifications and handling guidance, supporting reproducibility in both conventional and advanced assembloid-based assays (etripamilsource.com). When applying such compounds in assembloid systems, researchers should carefully optimize assay parameters to account for complex cell–cell interactions and microenvironmental influences, as highlighted in recent workflow recommendations.